Table 1: Clinical characteristics of the total sample and across ABO blood group.
Variable | Total | Blood group O | Blood group A | Blood group B | P-value | |
N (%) | N (%) | N (%) | N (%) | |||
n | 215 | 90 (41.9%) | 85 (39.5%) | 40 (18.6%) | ||
Age in years (Mean ± SD) | 61.87 ± 6.14 | 62.14 ± 5.54 | 61.76 ± 6.56 | 62.07 ± 6.35 | 0.818 | |
Gleason Score (GS) | < = 6 | 71 (33.0%) | 33 (36.7%) | 21 (24.7%) | 17 (42.5%) | |
7 | 112 (52.1%) | 40 (44.4%) | 54 (63.5%) | 18 (45.0%) | ||
> = 8 | 32 (14.9%) | 17 (18.9%) | 10 (11.8%) | 5 (12.5%) | 0.080 | |
Extraprostatic Extension (EPE) | No | 155 (72.1%) | 68 (75.6%) | 56 (65.9%) | 31 (77.5%) | |
Yes | 60 (27.9%) | 22 (24.4%) | 29 (34.1%) | 9 (22.5%) | 0.253 | |
Surgical Margin (SM) | No | 107 (49.8%) | 45 (50.0%) | 41 (48.2%) | 21 (52.5%) | |
Yes | 108 (50.2%) | 45 (50.0%) | 44 (51.7%) | 19 (47.5%) | 0.904 | |
Seminal Vesicle Involvement (SVI) | No | 189 (87.9%) | 80 (88.9%) | 72 (84.7%) | 37 (92.5%) | |
Yes | 26 (12.1%) | 10 (11.1%) | 13 (15.3%) | 3 (7.5%) | 0.429 | |
Pathological stage (PT) | T2a, T2b | 48 (22.3%) | 19 (21.1%) | 18 (21.2%) | 11 (27.5%) | |
T2c | 103 (47.9%) | 46 (51.1%)d | 37 (43.5%) | 20 (50.0%) | ||
T3 | 64 (29.8%) | 25 (27.8%) | 30 (35.3%) | 9 (22.5%) | 0.589 | |
Adjuvant therapy | No | 160 (77.3%) | 70 (78.7%) | 64 (78.0%) | 26 (72.2%) | |
Yes | 47 (22.7%) | 19 (21.3%) | 18 (22.0%) | 10 (27.8%) | 0.723 | |
Pre-op PSA (Mean ± SD) | 8.89 ± 6.65 | 8.50 ± 5.62 | 9.94 ± 7.76 | 7.50 ± 5.90 | 0.128 |